Anzeige
Meldung des Tages: Technisches Qualitätssiegel: Diese Kupfer-News liefert Substanz – und genau das macht sie jetzt spannend

Heron Therapeutics Aktie News

Aktie
WKN:  A1XB6K ISIN:  US4277461020 US-Symbol:  HRTX Branche:  Biotechnologie Land:  USA
0,9785 €
-0,0125 €
-1,26%
09:33:16 Uhr
Depot/Watchlist
Marktkapitalisierung *
165,37 Mio. €
Streubesitz
14,94%
KGV
-27
Index-Zuordnung
Nasdaq Composite Index

Heron Therapeutics News

15.08.25 - PR Newswire
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value PR Newswire
08.08.25 - PR Newswire
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile PR Newswire
08.08.25 - PR Newswire
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 PR Newswire
28.07.25 - PR Newswire
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 PR Newswire
06.05.25 - PR Newswire
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates PR Newswire
06.05.25 - PR Newswire
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations PR Newswire
28.04.25 - PR Newswire
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer PR Newswire
27.02.25 - PR Newswire
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates PR Newswire

Newssuche

Videos

newspaper
18.02.26 0,00%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »